Crinetics Pharmaceuticals Inc. (CRNX) and Mustang Bio Inc. (NASDAQ:MBIO) Comparison side by side

Both Crinetics Pharmaceuticals Inc. (NASDAQ:CRNX) and Mustang Bio Inc. (NASDAQ:MBIO) compete on a level playing field in the Biotechnology industry. We will evaluate their performance with regards to profitability, analyst recommendations, risk, dividends, earnings and valuation, institutional ownership.

Table 2 provides us the return on equity, net margins and return on assets of both companies.

Net Margins

Return on Equity

Return on Assets

Crinetics Pharmaceuticals Inc.

-1,115.64%

0%

0%

Mustang Bio Inc.

0.00%

-65.1%

-60%

Liquidity

The Current Ratio and Quick Ratio of Crinetics Pharmaceuticals Inc. are 31 and 31 respectively. Its competitor Mustang Bio Inc.’s Current Ratio is 10.3 and its Quick Ratio is 10.3. Crinetics Pharmaceuticals Inc. can pay off short and long-term obligations better than Mustang Bio Inc.

Analyst Ratings

Crinetics Pharmaceuticals Inc. and Mustang Bio Inc. Recommendations and Ratings are available on the next table.

Sell Ratings

Hold Ratings

Buy Ratings

Rating Score

Crinetics Pharmaceuticals Inc.

0

0

1

3.00

Mustang Bio Inc.

0

0

0

0.00

Crinetics Pharmaceuticals Inc.’s upside potential currently stands at 54.74% and an $40 average target price.

Crinetics Pharmaceuticals, Inc., a clinical stage pharmaceutical company, focuses on the discovery, development, and commercialization of therapeutics for rare endocrine diseases and endocrine-related tumors. Its lead product candidate is CRN00808, an oral selective nonpeptide somatostatin receptor type 2 biased agonist, which is in Phase I clinical trials used for the treatment of acromegaly. The company is also developing CRN02481, an oral selective nonpeptide somatostatin type 5 receptor agonist used for the treatment of congenital hyperinsulinism; and CRN01941, an oral, selective nonpeptide sst2 biased agonist designed for the treatment of neuroendocrine tumors. Crinetics Pharmaceuticals, Inc. was incorporated in 2008 and is headquartered in San Diego, California.

Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of novel cancer immunotherapy products based on the chimeric antigen receptor engineered T cell technology. Its lead programs include MB-101 for the treatment of brain cancer that is in Phase I trials; and MB-102, a therapeutic agent in acute myeloid leukemia, which is in Phase I trials. The company was incorporated in 2015 and is based in New York, New York. Mustang Bio, Inc. is a subsidiary of Fortress Biotech, Inc.

Disclaimer: StocksBeat inform you that the data in this website is not necessarily real-time nor accurate. All prices are not provided by exchanges and prices may not be accurate and may differ from the actual market price, meaning prices are indicative and not appropriate for trading purposes. Therefore Stocksbeat doesn`t bear any responsibility for any trading losses you might incur as a result of using the data.